×
About 2,934 results
VENTANA PD-L1 (SP142) Assay - P160002/S009
https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm633972.htm

Mar 10th, 2019 - What is it? It is a test done in a laboratory using samples from triple negative breast cancer patients which doctors use to see if patients have programmed cell death ligand (PD-L1) in their cancer. When is it used? To help doctors decide whether atezolizumab is the best treatment choice for their patients. Atezolizumab is a drug that blocks PD-L1. Doctors use atezolizumab in combination wi...

Sangia Total PSA Test - P170037
https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm630197.htm

Jan 29th, 2019 - The Sangia Total Prostate Specific Antigen (PSA) Test consists of a Cassette Assembly and a Sample Collector. The Sangia Total PSA Test is used as an aid in the diagnosis of prostate cancer. This new test is the first point-of-care test that can deliver PSA results near where the patient is being evaluated, for example at the doctor's office, instead of waiting for lab analysis. The test can be...

TIBSOVO® (ivosidenib tablets) Prescribing Information
https://www.tibsovopro.com/pdf/prescribinginformation.pdf

Jul 19th, 2018 - TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test

Updated durvalumab monotherapy data confirm results in urothelial bladder cancer
https://www.astrazeneca.com/media-centre/press-releases/2017/updated-durvalumab-monotherapy-data-confirm-results-in-urothelial-bladder-cancer-17022017.html

Feb 16th, 2017 - AstraZeneca and its global biologics research and development arm, MedImmune, today announced updated efficacy and safety data for durvalumab in patients with locally-advanced or metastatic urothelial cancer (UC). Updated results from the Phase I/II trial, presented at the 2017 ASCO Genitourinary Cancers Symposium, showed an objective response rate (ORR) of 20.4% in all evaluable patients (n...

Abbott RealTime IDH1
https://www.molecular.abbott/us/en/products/oncology/realtime-idh1

An in vitro polymerase chain reaction (PCR) assay for the qualitative detection of single nucleotide variants (SNVs)

ACTIQ® (fentanyl citrate
http://www.actiq.com/

INDICATIONS AND USAGE. ACTIQ® oral transmucosal lozenge, CII is indicated for the management of breakthrough pain in cancer patients 16 years of age

ADCETRIS® (brentuximab vedotin)
http://adcetrisupdate.com/

Brentuximab vedotin is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

AFINITOR® (everolimus) tablets
http://hcp.novartis.com/products/afinitor/

AFINITOR® (everolimus) Tablets is contraindicated in patients with ... but alcohol-, hydrogen peroxide-, iodine-, or thyme-containing products should be avoided.

Axumin® (fluciclovine F 18)
https://www.axumin.com/

Learn about Axumin® (fluciclovine F 18) injection, a diagnostic imaging agent that can help detect and localize prostate cancer across local and distant sites of recurrence.

ARZERRA® (ofatumumab) INJECTION
http://hcp.novartis.com/products/arzerra/

Previously untreated chronic lymphocytic leukemia (CLL) ... In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.

COTELLIC® (cobimetinib)
https://www.gene.com/medical-professionals/medicines/cotellic

Find information about COTELLIC® (cobimetinib) in combination with ZELBORAF® (vemurafenib), approved for BRAF V600E or V600K(+) unresectable or metastatic melanoma. INDICATIONS AND USAGE: COTELLIC (cobimetinib) is indicated for the treatment of patients with unresectable or metastatic melanoma with a ...

BENDEKA® INJECTION (bendamustine HCl)
http://bendekahcp.com/

Learn more about BENDEKA (bendamustine HCl) injection, an intravenous chemotherapy for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL).

BLINCYTO® INJECTION (blinatumomab)
http://www.blincyto.com/

Find patient and HCP-focused information about BLINCYTO® (blinatumomab). Learn more about acute lymphoblastic leukemia (ALL). See Safety Info, including Boxed Warnings.

CYRAMZA® (ramucirumab)
http://www.cyramzahcp.com/

CYRAMZA, combined with other medications, is used for the treatment of patients with advanced gastric cancer or GEJ, metastatic non-small cell lung cancer (NSCLC), and metastatic colorectal cancer (mCRC).

ELIGARD (leuprolide acetate for injectable suspension)
http://eligardhcp.com/

Official HCP Web site for ELIGARD, a palliative treatment for advanced prostate cancer. Please see Important Safety Information.

Elitek (rasburicase) IV Infusion | Healthcare Professional Site
https://www.elitekpro.com/

The official HCP site for Elitek (rasburicase) for the initial management of plasma uric acid levels in adults and pediatric patients. See trial design, and Important Safety Information, including Boxed WARNING.

ELLENCE® (epirubicin HCl)
https://www.pfizermedicalinformation.com/en-us/ellence/indications-usage

ELLENCE Injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer

BUSULFAN INJECTION
http://www.sagentpharma.com/wpcproduct/busulfan-injection/

Busulfan Injection is an alkylating drug indicated for: Use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML)

clonoSEQ® Assay
https://www.adaptivebiotech.com/clonoseq/clonoseq-assay

CLONOSEQ IS THE 1ST AND ONLY FDA-CLEARED ASSAYfor the detection and monitoring of MRD in bone marrow samples from multiple myeloma and B-cell acute lymphoblastic leukemia (ALL) patients

CALQUENCE® (acalabrutinib) capsule
https://www.calquence.com/physician.html

CALQUENCE is a Bruton tyrosine kinase inhibitor indicated for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy.